248 413

Cited 133 times in

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

DC Field Value Language
dc.contributor.author정현철-
dc.contributor.author조재용-
dc.date.accessioned2020-09-28T11:09:04Z-
dc.date.available2020-09-28T11:09:04Z-
dc.date.issued2020-05-
dc.identifier.issn1436-3291-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/179171-
dc.description.abstractBackground: Nivolumab showed improvement in overall survival (OS) in ATTRACTION-2, the first phase 3 study in patients with gastric/gastroesophageal junction (G/GEJ) cancer treated with ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein. Methods: ATTRACTION-2 was a randomized, double-blind, placebo-controlled, phase 3 trial (49 sites; Japan, South Korea, and Taiwan). The median (min-max) follow-up period was 27.3 (24.1-36.3) months. The primary endpoint was OS. A subanalysis of OS was performed based on best overall response and tumor-programmed death ligand-1 (PD-L1) expression status. Results: Overall, 493 of 601 screened patients were randomized (2:1) to receive nivolumab (330) or placebo (163). OS (median [95% confidence interval; CI]) was significantly longer in the nivolumab group (5.26 [4.60-6.37] vs 4.14 [3.42-4.86] months in placebo group) at the 2-year follow-up (hazard ratio [95% CI], 0.62 [0.51-0.76]; P < 0.0001). A higher OS rate was observed in the nivolumab vs placebo group at 1 (27.3% vs 11.6%) and 2 years (10.6% vs 3.2%). The OS benefit was observed regardless of tumor PD-L1 expression. Among patients with a complete or partial response (CR or PR) in the nivolumab group, the median OS (95% CI) was 26.6 (21.65-not applicable) months; the OS rates at 1 and 2 years were 87.1% and 61.3%, respectively. No new safety signals were identified. Conclusions: Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer. The long-term survival benefit of nivolumab was most evident in patients with a CR or PR.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherSpringer-Verlag Tokyo-
dc.relation.isPartOfGASTRIC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleA phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorLi-Tzong Chen-
dc.contributor.googleauthorTaroh Satoh-
dc.contributor.googleauthorMin-Hee Ryu-
dc.contributor.googleauthorYee Chao-
dc.contributor.googleauthorKen Kato-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorJen-Shi Chen-
dc.contributor.googleauthorKei Muro-
dc.contributor.googleauthorWon Ki Kang-
dc.contributor.googleauthorKun-Huei Yeh-
dc.contributor.googleauthorTakaki Yoshikawa-
dc.contributor.googleauthorSang Cheul Oh-
dc.contributor.googleauthorLi-Yuan Bai-
dc.contributor.googleauthorTakao Tamura-
dc.contributor.googleauthorKeun-Wook Lee-
dc.contributor.googleauthorYasuo Hamamoto-
dc.contributor.googleauthorJong Gwang Kim-
dc.contributor.googleauthorKeisho Chin-
dc.contributor.googleauthorDo-Youn Oh-
dc.contributor.googleauthorKeiko Minashi-
dc.contributor.googleauthorJae Yong Cho-
dc.contributor.googleauthorMasahiro Tsuda-
dc.contributor.googleauthorHiroki Sameshima-
dc.contributor.googleauthorYoon-Koo Kang-
dc.contributor.googleauthorNarikazu Boku-
dc.identifier.doi10.1007/s10120-019-01034-7-
dc.contributor.localIdA03773-
dc.contributor.localIdA03899-
dc.relation.journalcodeJ00916-
dc.identifier.eissn1436-3305-
dc.identifier.pmid31863227-
dc.subject.keywordGastric cancer-
dc.subject.keywordGastroesophageal junction cancer-
dc.subject.keywordLong-term-
dc.subject.keywordNivolumab-
dc.subject.keywordPlacebo-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor조재용-
dc.citation.volume23-
dc.citation.number3-
dc.citation.startPage510-
dc.citation.endPage519-
dc.identifier.bibliographicCitationGASTRIC CANCER, Vol.23(3) : 510-519, 2020-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.